Page 7 - Development Scale News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article ResearchAndMarkets.com s offering. The report features an extensive study of the current market landscape and future opportunities associated with the microbial contract biomanufacturing market. The study also features a detailed analysis of key drivers and trends related to this evolving domain. Traditionally, microbial cell cultures have been the preferred choice for the production of the variety of biologics, including peptide therapeutics and certain low molecular weight proteins (insulin) and cytokines. Till date, over 60% of recombinant proteins used for therapeutic purposes, are estimated to be produced using microbial expression systems, primarily Escherichia coli. In fact, more than 70 biologics approved by various regulatory authorities, worldwide, are manufactured using microbial fermentation. It is worth highlighting that the growing interest in certain novel biologics, such as antibody fragments and plasmid DNA (with potential a

United statesLuina bioBoehringer ingelheim bioxcellenceAltor bioscienceAumgene biosciencesAkshaya bioAkers biosciencesAsia pacificPorton biopharmaArranta bioBiosynergy europeMax rossettoAxcellerate pharmaBristol myers squibbNorthway biotechpharmaStelis biopharma